3 Objectives. The ASAS/EULAR recommendations for the management of ankylosing spondylitis have been developed by rheumatologists for a target population of health professionals.. ASAS and EULAR agreed to extend their cooperation by translating the recommendations to a language that can be easily understood by patients in order to further disseminate and evaluate the recommendations.
Introduction:
Ankylosing spondylitis (AS), the main entity of the spondyloarthritides (SpA), is a chronic inflammatory disease characterized by specific musculoskeletal features: inflammation and ankylosis of the axial skeleton, peripheral arthritis, enthesitis and involvement of other organs such as the eye [1] . Major advances in the management of AS have been recently reached by introduction of magnetic resonance imaging (MRI) and the tumor necrosis factor (TNF)-α inhibitors [2, 3] . To assist all health professionals involved in the care of patients with AS, evidence based recommendations for the management of this disease were developed [4] . The Assessment of SpondyloArthritis International Society (ASAS) has recently published recommendations for the use of anti-TNF therapy in AS [5] , and together with the European League Against Rheumatism (EULAR) recommendations for the management of AS in 2006 (Supplement 1 and 2) based on a systematic literature search [6, 7] . These were drafted by a combination of evidence and expert consensus. Treatment recommendations for AS have also been released by the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada working group [8, 9] . The ASAS/EULAR recommendations were an important step forward in generating an international consensus on the appropriate management of AS. However, they have been developed by rheumatologists and orthopedic surgeons for a target population of mainly health professionals and payers, and the language of the publication is largely medical. In a chronic disease, sustainable patient knowledge is beneficial and patient input into the decision-making process of recommendations is a requirement by various institutions. The importance of patients' view and preference is also included in the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument for evaluation of guidelines [10] . However, the mechanism by which this is best accomplished has not been well defined. ASAS and EULAR have agreed to extend their cooperation by translating recommendations into a language that can be easily understood by patients. At a consensus meeting of rheumatologists and deputies of national patient organizations, the ASAS/EULAR recommendations for the Management of AS were translated into a language that can be understood by AS patients in order to further disseminate and evaluate the recommendations among patients.
Methods:
Participants: In cooperation with EULAR (PARE, People with Arthritis/Rheumatism in Europe), the Ankylosing Spondylitis International Federation (ASIF), the Deutsche Vereinigung Morbus Bechterew (DVMB), the National Ankylosing Spondylitis Society (NASS) and other national patient organizations, 18 AS patients (including one rheumatologist) of 10 different countries (Belgium, Canada, Germany, Ireland, the Netherlands, Portugal, Romania, Switzerland, Turkey, United Kingdom) were invited to attend a consensus meeting at the EULAR house near Zurich in February 2008. A planning committee was formed from within ASAS (J. Braun as convener, D. van der Heijde as clinical epidemiologist, H. Mielants as an experienced clinician and ASAS member), EULAR (M. de Wit) and ASIF (E. Feldtkeller). Demographic characteristics, partial history and current health status of the participants were collected. This included questions to be answered by a visual analog scale (VAS), the Bath AS Disease Activity Index (BASDAI) and the Bath AS Functional Index (BASFI).
Working document: As a starting point, the original publication and a version created by Canadian AS patients were used. K. Mulholland, an AS patient who was strongly involved in the Canadian project, attended the meeting to explain the development of this patient based version [9] . To improve the understanding of potential problems, data on the evaluation of a recent German translation of the experts version evaluated by patients were presented during the meeting [11] .
Translation process: Each participant of the consensus meeting was asked to contribute independently proposals relevant to the translation of the patient version of the ASAS/EULAR recommendations for the management of AS. The aim was to create a new manuscript that is produced and understood by patients. To achieve this, the main task was to translate the original text by simplifying the wording and to explain the original text by adding comments to a patient friendly version. However, it was stated at the beginning of the meeting that it was not allowed to modify the meaning of the original recommendations. After the participants had generated ten patient adapted recommendations, comments explaining difficult terms were discussed and a wish-list was developed for possible consideration in the next update of the ASAS/EULAR recommendations for the management of AS.
Evaluation: After intensive discussions a vote was held on the new translation of the recommendations aiming for a > 80% agreement on the translation. The participants had the option to agree (positive vote), to disagree (negative vote) or to be neutral (no vote) on translation of the patient version. In case of a negative vote the participants were asked to state the reason for their disagreement. Finally, based on the content of the recommendation, patients were asked to rate the strength of recommendation (SOR) on a numerical rating scale for each recommendation (0=not agree at all, 10=fully agree).
Results:
Characteristics of the participants: The baseline characteristics of the participants are given in Table 1 . Translation and evaluation of the patient version: Ten recommendations were successfully translated into a patient adapted version. The first 3 recommendations address general concepts in the management of AS, the remaining 7 describe specific treatments in use for AS. The original text was changed in most cases. Table 2 shows the full recommendations of the patient version; comments to each recommendation are presented in Table 3 , while the evaluation of the recommendations (translation and agreement) is shown in Table 4 . -The frequency of monitoring should be decided for each individual patient based on current symptoms, severity, and medication.
Recommendation 3: Management strategy
Optimal management 1 of AS requires the use of both drug and non-drug treatments.
Recommendation 4: Non-drug treatment
Non-drug treatment of AS should include patient education 2 and regular exercise. Individual and group physiotherapy 2 under the supervision of a qualified therapist should be considered. Patient associations and self help groups 2 may be useful.
Recommendation 5: Drug treatment -anti-inflammatory
-Anti-inflammatory drugs 1 (not including steroids) are recommended as first choice for patients with AS suffering from pain and stiffness.
-For patients with an increased risk of side effects in the stomach there are two options:
o an additional drug that protects the stomach, or o an anti-inflammatory drug with a reduced risk for side effects in the stomach (selective COX-2 inhibitor 1 ).
Recommendation 6: Drug treatment -pain killers
Pain killers such as paracetamol and opioids 1 might be considered for pain control when antiinflammatory drugs:
-have not provided sufficient relief, -have caused unacceptable side effects, -cannot be used because of other medical reasons. -The benefit of steroids given in other ways is not proven when the disease is only present in the spine.
Recommendation 8: Drug treatment -DMARDs
-It is not proven that so-called disease modifying drugs (DMARDs 1 ), such as sulfasalazine 2 and methotrexate, are effective for the treatment of AS in the spine.
-Sulfasalazine may be effective in those patients who have inflammation in joints outside the spine.
Recommendation 9: Drug treatment -anti-TNF
-If the treatments outlined above do not control disease activity sufficiently, anti-TNF 1 drugs should be given in line with the ASAS recommendations 1 .
-It is not necessary to use DMARDs before or along with anti-TNF treatment in those patients who only have disease in the spine.
Recommendation 10: Surgery
-Total hip replacement 1 should be considered, regardless of age, in patients with pain or disability not responding to treatment and where there is x-ray evidence of joint damage.
-Spinal surgery may be of value to correct severe deformity 1 or stabilize 1 the spine. required in the EULAR standardized operating procedures [12] . The original ASAS/EULAR recommendations for the management of AS published more than 2 years ago have already been evaluated in different countries [4, [15] [16] [17] . In Canada, a first effort has been undertaken to try this also on the patient level [9] . Support of patient knowledge and participation in the management of chronic diseases is likely to be beneficial since it is well established that one powerful strategy to change behavior of patients is to involve them directly in the development of guidelines or recommendations [18] . This is the first time that patient-adapted recommendations for the management of AS have been developed with direct participation of patients in a consensus meeting. Hereby the ten key recommendations of the expert's version (Supplement 1) were successfully translated into a patient understandable language (Table 2) . Indeed, the notable and most important experience in this meeting was that it was no great problem to agree on this patient adapted version of the recommendations for the management of AS among a rather mixed group of AS patients from 10 different European countries. The involvement of patients with many different native tongues enhances the likelihood that the present language version can be easily understood by many patients and also easily translated in various languages as specific English wording is avoided. Although there was a lot of discussion, it was eventually possible to agree on the basis of a majority vote with > 80% agreement in almost all cases. Participants accepted that the basic content of the original recommendations could not be changed during this translation process. Considerable time was spent on discussions relating to the content of the recommendations (importance of nonpharmacological treatment options, use of opioids and corticosteroids etc.). The patients prepared a wish-list for further consideration in the next update of the recommendations, in which most of the discussion regarding the content is summarized (Table 5) . Despite the discussion to discriminate between agreement with the translation versus with the content of the patient version, it is quite obvious that in some cases (e.g. recommendation No. 4) the patients vote to the translation is influenced by disagreement to the content of the recommendation. This difficulty can be reduced if the AS patients will be able to participate in the development of recommendations at earlier steps. This patient version of the ASAS/EULAR recommendation for the management of AS should serve as a preliminary step for the development of the ASAS/EULAR management recommendation update and also for further evaluation and dissemination in individual countries where a broader array of patients should be included. Thus, the patient version will be forwarded to ASAS members in all EULAR countries with the request to perform a translation in cooperation with national patient organization. Within this national translation process the group of participants should be heterogeneous concerning disease status and educational level. This was not the case in our group of AS patients because the success of creating an international patient version depends on excellent knowledge of the English language of all participants. The dissemination and evaluation of the national patient versions will be checked after one year. The participants elaborate during the discussion that not only body functions and structures have to be discussed as an important aspect of disease progress (recommendation No. 1). In terms of the composition of the International Classification of Functioning, Disability and Health developed by the WHO for describing functioning of people with an ill health condition the aspects of activity and participation of the patients have to be considered as well [13] . In this framework function is not narrowed to biomedical function but environmental and personal factors are in a complex interaction of these areas. Recently, this has already been applied to patients with AS [14] . The study on dissemination and evaluation of the health professionals publication of the ASAS/EULAR recommendations for the management of AS among European rheumatologists has already shown that conceptual agreement with the recommendations was very high, as was self-declared application by rheumatologists (8.9 ± 0.9 and 8.2 ± 1.0, respectively) [15] . Potential barriers to the application of the ASAS recommendations include primarily insufficient funding and administrative burden for anti-TNF therapy and patient concern about safety of pharmacological therapy. Barriers to the use of the non-pharmacological treatment are lack of consultation time, insufficient number of qualified physiotherapists, lack of facilities for education and lack of patient compliance with recommendations. Similar to the European evaluation, a broad agreement with the recommendations was achieved to an evaluation in the German language area and in Mexico [16, 17] .
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For the first time, EULAR recommendations were successfully converted into lay terms by a large international task force of patients in collaboration with rheumatologists. This can be seen as a starting point for the dissemination and implementation of the patient version to provide guidance for monitoring and treatment of patients with AS. Further translations into different languages and appropriate evaluations in larger patient groups will be performed. NSAIDs are recommended as first line drug treatment for patients with AS with pain and stiffness. In those with increased GI risk, non-selective NSAIDs plus a gastroprotective agent, or a selective COX-2 inhibitor could be used 6 Analgesics, such as paracetamol and opioids, might be considered for pain control in patients in whom NSAIDs are insufficient, contraindicated, and/or poorly tolerated 7 Corticosteroid injections directed to the local site of musculoskeletal inflammation may be considered. The use of systemic corticosteroids for axial disease is not supported by evidence 8 There is no evidence for the efficacy of DMARDs, including sulfasalazine and methotrexate, for the treatment of axial disease. Sulfasalazine may be considered in patients with peripheral arthritis 9 Anti-TNF treatment should be given to patients with persistently high disease activity despite conventional treatments according to the ASAS recommendations. There is no evidence to support the obligatory use of DMARDs before, or concomitant with, anti-TNF treatment in patients with axial disease 10 Total hip arthroplasty should be considered in patients with refractory pain or disability and radiographic evidence of structural damage, independent of age. Spinal surgery -for example, corrective osteotomy and stabilisation procedures, may be of value in selected patients.
